ĐÁNH GIÁ KẾT QUẢ ĐIỀU TRỊ UNG THƯ PHỔI TẾ BÀO NHỎ GIAI ĐOẠN LAN TRÀN BẰNG PHÁC ĐỒ ETOPOSIDE - CISPLATIN TẠI BỆNH VIỆN ĐẠI HỌC Y HÀ NỘI

Abstract

Objective: To evaluate the treatment outcomes of the Etoposide - Cisplatin regimen in patients with extensive-stage small cell lung cancer. Methods: A cross-sectional descriptive study was conducted on 39 patients with extensive-stage small cell lung cancer who received Etoposide - Cisplatin at Hanoi Medical University Hospital from June 2017 to June 2025. Results: The mean age of patients was 61,2 years, with the majority being male. According to RECIST 1.1 criteria, the complete response (CR) rate was 7,7%, partial response (PR) rate was 64,1%, stable disease (SD) was observed in 12,8%, and progressive disease (PD) in 15,4%. The median progression-free survival (PFS) was 6,5 months, and the median overall survival (OS) was 10 months. The most common hematologic toxicity was neutropenia, observed in 51,2% of cases (Grade 1–2: 38,4%; Grade 3–4: 12,8%), followed by anemia in 30,8% of cases (Grade 1–2: 28,2%; Grade 3–4: 2,6%). The most frequent non-hematologic adverse event was nausea, occurring in 30,8% of patients (Grade 1–2: 28,2%; Grade 3–4: 2,6%), and elevated creatinine was seen in 12,8% (Grade 1–2: 12,8%; Grade 3–4: 0%). Conclusions: The Etoposide – Cisplatin regimen demonstrates good therapeutic efficacy in patients with extensive-stage small cell lung cancer, with an acceptable level of toxicity.